Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




International Gene Mapping Study Identifies More Genes Linked to Cardiovascular Disease Risk

By LabMedica International staff writers
Posted on 20 Dec 2012
A large study focusing on the genetics of cardiovascular disease (CAD) identified several significant molecular pathways mapping to networks linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD.

The study was carried out under the aegis of the CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease) consortium, hosted by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom). More...
This consortium represents a collaborative effort to combine data from multiple large-scale genetic studies to identify risk loci for coronary artery disease and myocardial infarction.

The latest study from the CARDIoGRAMplusC4D Consortium combined the efforts of 180 researchers from countries across Europe (United Kingdom, Germany, Iceland, Sweden, Finland, The Netherlands, France, Italy, and Greece) as well as Lebanon, Pakistan, Korea, USA, and Canada. These laboratories analyzed DNA samples from more than 60,000 CAD cases and 130,000 normal controls.

Results published in the December 2, 2012, online edition of the journal Nature Genetics identified 15 genetic regions newly associated with the disease, bringing to 46 the number of regions associated with CAD risk. A further 104 independent variants strongly associated with CAD were found, which account for approximately 10.6% of inherited CAD genes. The four most significant pathways mapping to these networks were linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD.

Of the 46 genome-wide significant lead single-nucleotide polymorphisms (SNPs), 12 showed a significant association with a lipid trait, and five showed a significant association with blood pressure, but none was significantly associated with diabetes.

"The importance of the work is that while some of the genetic variants that we have identified work through known risk factors for CAD such as high blood pressure and cholesterol, many of the variants appear to work through unknown mechanisms," said senior author Dr. Nilesh Samani, professor of cardiology at the University of Leicester (United Kingdom). "Understanding how these genetic variants affect CAD risk is the next goal and this could pave a way to developing new treatments for this important disease."

Related Links:

Wellcome Trust Sanger Institute
University of Leicester



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.